Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models
Whereas MET inhibitors are effective in MET-active tumors, MET-CAR T cells eradicate MET-positive GBM growth in an antigen-dependent manner, demonstrating a promising therapeutic approach for treating MET-positive GBM. MET overexpression, especially MET<sup>amp</sup> and ZM fusion may be used to predefine the GBM patients for treating with MET-CAR T cell therapy.
Authors
- Johanna Preiszner
- Benjamin Hilton (ORCID: https://orcid.org/0000-0002-2126-9434)
- Anna Qin
- Anna Musket
- Michael E. Berens (ORCID: https://orcid.org/0000-0002-3382-6787)
- Mingyao Ying (ORCID: https://orcid.org/0000-0002-6215-4959)
- Giedre Krenciute (ORCID: https://orcid.org/0000-0003-4335-0644)
- Phillip R. Musich (ORCID: https://orcid.org/0000-0001-8816-4242)
- Qian Xie (ORCID: https://orcid.org/0000-0003-4206-1736)
Institutions
- East Tennessee State University (US)
- Translational Genomics Research Institute (US)
- Kennedy Krieger Institute (US)
- St. Jude Children's Research Hospital (US)
- Johns Hopkins University (US)
- Greenwood Genetic Center (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1186/s12967-025-06475-6
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- East Tennessee State University
- St. Jude Children's Research Hospital
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke